Aranesp Solution For Injection 100Mcg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Aranesp: Solution for injection (100mcg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

DARBEPOETIN ALFA (dar be POE e tin AL fa) helps your body make more red blood cells. It is used to treat anemia caused by chronic kidney failure and chemotherapy.

In-Depth Information
Select a Medication

Aranesp 100mcg/ml Solution for Injection

NDC: 555130005
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved





Sometimes used for but not FDA approved for the following conditions:
Anemia

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Do not use if product has been frozen
Discard product if it contains particulate matter, is cloudy, or discolored
Store in carton until time of use
Discard unused portion. Do not store for later use.
Protect from freezing
Aranesp 100mcg/ml Solution for Injection

Reported Side Effects for Aranesp 100mcg/ml Solution for Injection

Heart Attack Incidence:
0.6%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Lung Incidence:
1.3%*
Severity: SEVERE
Onset: DELAYED
Brain Attack Incidence:
1.7-2.1%*
Severity: SEVERE
Onset: EARLY
Skin Redness Incidence:
5.0%*
Severity: MODERATE
Onset: EARLY
Skin Rash Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Blood Clot Incidence:
5.0%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
8.0%*
Severity: MODERATE
Onset: EARLY
Cough Incidence:
12.0%*
Severity: MILD
Onset: DELAYED
Swelling Incidence:
12.8%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
13.2%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
17.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
17.0%*
Severity: MODERATE
Onset: EARLY
High Blood Pressure Incidence:
31.0%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Aranesp

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5